September 14, 2014

Asthma and respiratory physiology: Putting lung function into perspective

September 13, 2014

A genome-wide association study of bronchodilator response in asthmatics


Pharmacogenomics J. Author manuscript; available in PMC Aug 1, 2014.
Published in final edited form as:
Published online Mar 19, 2013. doi:  10.1038/tpj.2013.5
PMCID: PMC3706515
NIHMSID: NIHMS442409

A genome-wide association study of bronchodilator response in asthmatics

Qing Ling Duan, PhD,1,* Jessica Lasky-Su, ScD,1,* Blanca E. Himes, PhD,1,2 Weiliang Qiu, PhD,1 Augusto A. Litonjua, MD, MPH,1,3 Amy Damask, PhD,5 Ross Lazarus, MB, BS,1 Barbara Klanderman, PhD,1 Charles G. Irvin, PhD,6Stephen P. Peters, MD, PhD,7 John P. Hanrahan, MD, MPH,8 John J. Lima, PharmD,9 Fernando D. Martinez, MD,10David Mauger, PhD,11 Vernon M. Chinchilli, PhD,11 Manuel Soto-Quiros, PhD,12 Lydiana Avila, MD,12 Juan C. Celedón, MD, DrPH,13 Christoph Lange, PhD,4 Scott T. Weiss, MD, MS,1,2,3,4 and Kelan G. Tantisira, MD, MPH1,3

Severe Asthma Study – Rob Oliphant - Asthma Society of Canada


Robert Oliphant is the President and CEO of the Asthma Society of Canada.  Rob is the President of the Global Allergy and Asthma Patient Platform and serves on the Steering Committee of Better Care Faster and the Governing Council of the Health Charities Coalition of Canada and was on the Steering Committee for the National Lung Health Framework. In 2013 he was awarded the Queen’s Diamond Jubilee Medal by the Governor General of Canada in recognition of his contributions to Canada.  From 2008 to 2011, Rob served as Member of Parliament of Canada, representing the riding of Don Valley West in the House of Commons.  Rob received his Bachelor of Commerce from the University of Toronto. He has a Masters of Divinity from the Vancouver School of Theology, at the University of British Columbia, and a Doctorate from the Chicago Theological Seminary at the University of Chicago.

Health Impact of Air Quality – Michael Brauer - Asthma Society of Canada


Michael Brauer is a Professor in the School of Population and Public Health at The University of British Columbia. He also directs the Bridge Program – a strategic training program linking public health, engineering and policy. His research focuses on the assessment of exposure and health impacts of air pollution, with specific interest in transportation-related and biomass air pollution. He has participated in monitoring and epidemiological studies throughout the world and served on advisory committees to the World Health Organization, the US National Academy of Sciences, the Royal Society of Canada, the International Joint Commission and governments in North America and Asia. He is an Associate Editor of Environmental Health Perspectives.


Corticosteroids in the treatment of acute asthma


REVIEW ARTICLE
Year : 2014  |  Volume : 9  |  Issue : 4  |  Page : 187-192
Abdullah A Alangari
Department of Pediatrics, College of Medicine, King Saud University, Riyadh, Saudi Arabia

Date of Submission    09-Dec-2013
Date of Acceptance    10-Mar-2014
Date of Web Publication    4-Sep-2014


DOI: 10.4103/1817-1737.140120

Small airway dysfunction is associated to excessive bronchoconstriction in asthmatic patients

Research

Open Access
Veronica Alfieri1Marina Aiello1Roberta Pisi1Panagiota Tzani1Elisa Mariani1Emilio Marangio1Dario Olivieri1Gabriele Nicolini2 and Alfredo Chetta1*

1Clinical & Experimental Medicine Department, University of Parma, Padiglione Rasori, via G. Rasori 10, Parma, 43125, Italy
2Corporate Clinical Development, Chiesi Farmaceutici S.p.A, Parma, Italy
For all author emails, please log on.

Respiratory Research 2014, 15:86  doi:10.1186/s12931-014-0086-1

The electronic version of this article is the complete one and can be found online at:http://respiratory-research.com/content/15/1/86

Received:1 April 2014
Accepted:20 July 2014
Published:27 August 2014
© 2014 Alfieri et al.; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

September 12, 2014

Current evidence of epidermal barrier dysfunction and thymic stromal lymphopoietin in the atopic march



Japanese guideline for occupational allergic diseases 2014


REVIEW ARTICLE

Kunio Dobashi, Kazuo Akiyama, Atsushi Usami, Hiroo Yokozeki, Zenro Ikezawa, Naomi Tsurikisawa, Yoichi Nakamura, Kazuhiro Sato, Jiro Okumura, on behalf of Committee for Japanese Guideline for Diagnosis and Management of Occupational Allergic Diseases and Japanese Society of Allergology [About this authors]

September 11, 2014

Placebo Controlled Randomised Trial of Medical Therapy in Otitis Media with Effusion


Glenis Kathleen Scadding* , Allergy & Rhinology , University College London , United Kingdom
Yvonne Colette Darby , Allergy & Rhinology , Royal National TNE Hospital
Anna Jansz , Allergy & Rhinology , RNTNE Hospital, London
David Richards , Respiratory , *Glaxo Smith Kline, Stevenage.
Helen Tate , Statistics , MSD Hertford Rd, Hoddesdon, EN11 9BU
Simon Gane , ENT Surgery , University College London

September 10, 2014

Severe Asthma Phenotyping: The Applicability of Current Proposols in Daily Practice









Research Article
Volume 1 Issue 1 - 2014
Adile Berna Dursun1,2*, Ferda Oner Erkekol2 and Ozlem Kar Kurt2,3
1Department of Internal Medicine, Division of Immunology and Allergic Diseases, Recep Tayyip Erdogan University School of Medicine, Turkey
2Divison of Immunology and Allergic Diseases, Ataturk Chest Disease and Thoracic Surgery Trainig and Research Hospital, Turkey
3Department of Respiratory Medicine, Izzet Baysal University School of Medicine, Turkey
Received: August 12, 2014 | Published: August 21, 2014
*Corresponding author: Adile Berna Dursun, Department of Internal Medicine, Division of Immunology and Allergic Diseases, Recep Tayyip Erdogan University School of Medicine, Rize, Turkey, Tel: 905325874868; Email: @
Citation: Dursun AB, Erkekol FO, Kurt OK (2014) Severe Asthma Phenotyping: The Applicability of Current Proposols in Daily Practice. J Lung Pulm Respir Res 1(1): 00003. http://dx.doi.org/10.15406/jlprr.2014.01.00003
  

Abstract

Background: Severe asthma (SA) is also need to be phenotyping. We aimed to demonstrate the applicability of current definition and classification proposals in daily practice.
Methods: SA patients, according to WHO definition of treatment resistant SA, were enrolled from the allergy clinic. The SARP algorith define and WHO proposal were applied to the subjects independently by asthma experts. Demographic and clinical characteristics of the subjects were used for the comparison.
Results: Ninety-five (F/M: 68/27) patients with a mean age of 45.97± 9.44 years (range25-71) were enrolled. The patients were grouped as controlled treatment-resistant SA (56%) and uncontrolled treatment resistant SA group (44%). There was no statistically significant difference between the groups but aspirin hypersensitivity. 49% of patients was classified as exacerbators, 26% as fixed airway obstruction group and 23% as undefined (other 2%). Age and mold sensitivity was higher; FEV1/FVC and FEF25-75 were lower in exacerbation-prone SA. More than half of the patients were define clustered at 4 and 5 according to SARP proposol. Patients with fixed obstruction were only in the clusters 4 and 5.
Conclusion: Current phenotyping proposols failed to cover all SA patients. Thus, there is still need further investigations in order to explore validity and applicability of the phenotyping of SA.
Keywords: Adult asthma; Severe asthma; Phenotype; Cluster analysis; Refractory asthma; Difficult-to-treat asthma

PDF   |   Full Text

September 8, 2014

Component resolved diagnosis: when should it be used?

Email updates

Keep up to date with the latest news and content from Clinical and Translational Allergy and BioMed Central.

Open AccessReview

Component resolved diagnosis: when should it be used?

Olga Luengo and Victòria Cardona

Citation

Abstract (provisional)

The knowledge on molecular allergy diagnosis is continuously evolving. It is now time for the clinician to integrate this knowledge and use it when needed to improve the accuracy of diagnosis and thus provide more precise therapeutic and avoidance measures. This review does not intend to comprehensively analyze all the available allergen molecules, but to provide some practical clues on use and interpretation of molecular allergy diagnosis. The potential role of component resolved diagnosis in circumstances such as the indication of allergen immunotherapy, pollen polysensitization, food allergy, latex allergy or anaphylaxis, is assessed. Interpreting the information provided by molecular allergy diagnosis needs a structured approach. It is necessary to evaluate single positivities and negativities, but also to appraise "the big picture" with perspective.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.


September 6, 2014

Anti-Inflammatory Effect of IL-37b in Children with Allergic Rhinitis

Mediators of Inflammation
Volume 2014 (2014), Article ID 746846, 13 pages
http://dx.doi.org/10.1155/2014/746846
Research Article
1Department of Otolaryngology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical College, No. 9 Jinsui Road, Guangzhou 510623, China
2Department of Otolaryngology, Head and Neck Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, No. 1665 Kongjiang Road, Shanghai 200092, China
Received 9 December 2013; Revised 4 July 2014; Accepted 14 July 2014; Published 11 August 2014
Academic Editor: Arkadiusz Orzechowski
Copyright © 2014 Wenlong Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Interleukin-37 (IL-37), a newly described member of IL-1family, functioned as a fundamental inhibitor of innate inflammatory and immune responses, especially its isoform IL-37b. Objective. This study was undertaken to evaluate the expression and regulation of IL-37b in children with allergic rhinitis (AR).Methods. Forty children with AR and twenty-five normal controls were included. The relationship between IL-37b and Th1/2 cytokines production in serum and nasal lavage was examined by enzyme-linked immunosorbent assay (ELISA). Peripheral blood mononuclear cells (PBMCs) were purified for in vitro regulation experiment of IL-37b. Intranasal mometasone furoate was given in AR children and IL-37b change after one-month treatment was detected using ELISA. Results. We observed significantly decreased IL-37b expression levels in both serum and nasal lavage compared to controls. IL-37b was negatively correlated with Th2 cytokines. Our results also showed that IL-37b downregulated Th2 cytokine expressed by PBMCs and this modulation was through mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) pathway. We also found that intranasal mometasone furoate therapy can promote nasal IL-37b expression.Conclusion. IL-37b may be involved in Th2 cytokine regulation in AR and its expression was related to the efficacy of intranasal steroid therapy.